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Introduction: Growing evidence has brought stem cell therapy to the forefront as new promising approaches
towards stroke treatment. Of all candidate seeding cells, adipose-derived stem cells (ADSCs) are considered as one of
the most appropriate for stroke treatment. However, previous experimental data could not reach to an agreement on
the efficacy of ADSC transplantation for treating stroke in vivo as well as its mechanism which hinders their further
clinical translational application.
Methods: To explore their in vivo mechanism of hADSC administration on neurological injury, hADSC were labeled
with Enhanced Green Fluorescence Protein expressing FG12 lentivirus and injected into MCAO mouse infarct area by in
situ way. Neurological function was evaluated by Rogers Scaling System and their spatial learning and memory was
determined by Morris Test. 2,3,5-triphenyltetrazolium chloride was carried out to compare the infarct area among
groups. Histoimmunostaining was used to track the injected hADSCs for their in vivo migration, transdifferentiation and
integration with the endogenous neuronal circuitry. To better address the underlying rescuing mechanism, qRT-PCR
was performed on neural markers of MBP, MAP2, GFAP, microglia marker of Iba1.
Results: It was found that hADSCs could promote both spatial learning and memory of MCAO mice. Co-localization of
GFP and MAP2 were found in the whole cortex with significantly (P<0.01) higher percentage at the contralateral cortex
compared with the ipsilateral cortex. Low percentage of GFP and GFAP co-localized cells were found at whole cortex.
Meanwhile, Iba1+ microglia and GFAP+ astrocyte cells were significantly (P<0.05) suppressed by hADSC injection.
Conclusions: hADSCs could transdifferentiate into neuron like cells (MAP2+) in vivo and probably used as seeding cells
for replacement based stem cell therapy of stroke. Also, significant immunomodulation was found. Meanwhile hADSCs
could significantly protect the endogenous neuron survival. This study demonstrated that hADSC intervention with
MCAO mice could apparently ameliorate stroke symptoms by direct cell replacement, enhanced immnunosuppression
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Stroke is one of the most devastating diseases and most
survivors suffer persistent and severe neurologic deficits in-
cluding motor, sensory, and cognitive dysfunctions. No
treatment for improving the outcome, other than i.v.
thrombolysis, has been shown to be effective in clinical
practice; however, the narrow therapeutic time window
makes thrombolysis treatment a possibility for only a small
percentage of patients [1]. Incipient protective therapies
have consistently failed as they have been directed towards
neural cells, whereas, after a stroke, not only neurons but
all components of the neurovascular unit are compromised
[2]. These problems represent the major challenges to be
overcome by stem cell-replacement therapy.
Several studies in preclinical stroke models have
shown that brain damage after stroke not only leads to
neuron loss but also to a dramatic decrease of brain
plasticity [3] and new therapeutic strategies should focus
not only on replenishing lost neurons and promoting en-
dogenous neurogenesis but also on enhancing other re-
lated processes, such as gliagenesis, oligodendrogenesis,
remyelination, synaptic plasticity, axonal sprouting, and
angiogenesis in order to improve neurological function.
The presence of stem cells in different structures of the
organism suggests that these cells are involved in natural
cell-renewal and repair of tissues throughout the lifespan
of an individual; therefore, the administration of stem
cells seems to modulate these endogenous mechanisms
involved in brain plasticity [4]. In this sense, stem cells,
in particular mesenchymal stem cells (MSCs), fulfill all
these requirements. These cells can be obtained from
various tissues and were originally described as adherent
cells with a fibroblast morphology and the capability of
differentiating into cells of mesodermal origin, such as
osteocytes, chondrocytes, and adipocytes [5]. They also
show the ability to differentiate into different embryonic
layers such as ectoderm and endoderm with excellent
self-renewal capacity [6]. Although being initially identi-
fied from bone marrow (BMSCs), MSCs have also been
successfully isolated from adipose tissue, pancreas, liver,
skeletal muscle, dermis, synovial membrane, trabecular
bone [7-9], umbilical cord blood [10], lung tissue [11], and
dental pulp and periodontal ligament [12]. Adipose-
derived stem cells (ADSCs) possess several advantages in-
cluding abundance, easy accessibility, active self-renewal
with low senescence, being free from ethical debate and
low immunogenicity, compared with other mesenchymal
stem cells and may represent one of the most interesting
sources for cell-replacement therapy [13-16]. Comparing
the effects of intravenous administration of both BMSCs
and ADSCs for stroke therapy in middle cerebral artery
occlusion (MCAO) models, both demonstrated significant
therapeutic effects but ADSC treatment seems more
beneficial [17,18]. Lack of expression of MHC-II inADSCs also advocates their allogeneic administration and
possibly allows ADSCs from healthy and younger donors
to be stored in biobanks for the treatment of stroke pa-
tients during the acute phase of the disease [4].
The functional outcome of allogeneic ADSC intervention
with neurological injury was mainly observed through bio-
medical studies. Most available reports have demonstrated
functional recovery after ADSC injection [17,19-22]. Despite
all these beneficial effects of ADSC therapy on stroke out-
come, the mechanisms involved in this functional process
still remain elusive and should be studied in greater depth.
Previous studies have demonstrated that allogeneic
ADSCs can survive in brain parenchyma [23] and ex-
press characteristic markers of neurons and glial cells
(microtubule-associated protein 2 (MAP2) and glial fi-
brillary acidic protein (GFAP), respectively) when
injected into the lateral ventricle of the rat brain after
MCAO [21]. Another study has reported that the intro-
duced exogenous ADSCs expressed endothelial markers
(von Willebrand factor (vWF) and endothelial barrier
antigen), but not neuronal or glial markers [22]. Never-
theless, the low number of donor cells found in the le-
sion area could suggest that the ADSCs suffer from
apoptotic death or autophagia in the weeks following
their administration. It is well-established that cell inte-
gration is not enough to explain the improvement in the
functional deficits. The beneficial effects of stem cell
therapy are probably also mediated by other important
mechanisms. In line with these observations, several
studies have reported that after intravenous administra-
tion, ADSCs were not yet fully implanted into the infarct
area [18,20], suggesting that it might not be necessary
for stem cells to migrate and graft into the lesion site in
order to obtain a positive functional recovery [24].
There is accumulating evidence suggesting that
ADSCs could secrete several trophic factors after post-
stroke administration, including brain-derived neuro-
trophic factor (BDNF) [20], insulin-like growth factor-1
(IGF-1) [25], vascular endothelial growth factor (VEGF),
and hepatocyte growth factor (HGF) [18], which could
be involved in the functional improvement of stroke
symptoms in animal models via the reduction in brain
injury-derived apoptosis and enhancement of the natural
repair response activated by brain injury. Therefore, the
secretion of trophic factors by ADSCs could play an im-
portant role in reducing cellular apoptosis incurred by
cerebral ischemic injury, partly by promoting the expres-
sion of Bcl-2, which participates in apoptotic signaling
after mitochondrial damage, and by inhibiting the ex-
pression of caspase-12, which mediates endoplasmic
reticulum stress-induced apoptosis [26]. Moreover,
ADSC administration decreased cell death [17,22,23] by
preventing nitric oxide release in response to cerebral is-
chemia [27].
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of the cell-free extract from ADSC culture in different in-
jury models, such as oxidative stress and cerebral ischemia.
They reported that the cell free complex mixture itself is
capable of exerting a protective activity [19,28]. This pro-
tective role is observed under different stress conditions in-
cluding in vitro models of cerebral infarct (oxygen and
glucose deprivation), and also in vivo models (transitory
and permanent focal cerebral ischemia and intra-cerebral
hemorrhage). More importantly, recent data also suggest
that direct communication might occur between the in-
jured brain and administered cells. Furthermore, it has been
shown that oxidative stress stimulates the activation of p38
mitogen-activated protein kinases (MAPK) and expression
of recombinant human bone morphogenetic protein 2
(BMP2) and basic fibroblast growth factor (bFGF) in hu-
man ADSC cultured in vitro [29]. This result may indicate
that treatment with ADSCs can be considered a ‘living/
responding treatment’ that is capable of responding to and
modulating the secretion of specific trophic factors under
stress environments. In vitro study discovered that ADSCs
modulate the immune system through suppressing prolifer-
ation of stimulated peripheral blood mononuclear cells and
inhibiting differentiation of monocyte-derived immature
dendritic cells. Moreover, in vitro cultures showed a higher
level of secretion of the cytokines that have been implicated
in the immunomodulatory modes of action of multipotent
stromal cells, such as IL-6 and transforming growth factor-
1 (TGF-1) [30,31]. In addition, ADSC has been shown to
attenuate the levels of IL-18, toll-like receptor (TLR)-4, and
plasminogen activator inhibitor-1 (PAI-1) [23]. However,
little is known about the immunomodulatory effects of
ADSC administration in vivo after stroke. These points are
surely relevant for recovery and should be analyzed in fu-
ture research.
In all, previously published data did not reach an agree-
ment on how ADSC works in vivo. Different animal
models, various ADSC delivery methods (intravenous de-
livery or in situ injection), different ADSC donors (allo-
geneic or autologous), tracing time (shorter or longer) and
ADSC intervention time window (acute or subacute) may
largely contribute to the treatment outcome as well as
their underlying mechanism. This study chose human
ADSCs (hADSCs) as the donor cells to treat a wild type
C57/BL6 derived stroke mouse model seven days after
surgery by an in situ injection method to observe their
therapeutic effects at the subacute phase. Immunogenicity,
immunomodulation and exogenous cell survival/integra-
tion were analyzed. The functional recovery was evaluated
by the Rogers Scale system and Morris Maze assay.
Methods
All animal experiments were performed according to proto-
cols approved by the Ethical Committee of the ExperimentalAnimal Center affiliated with the Medicine School of Tongji
University. The approval No. is TJLAC-014-012. hADSCs
were isolated from human adipose liposuction liquid, and
the processing and handling protocols were approved by the
Ethical Committee of the East Hospital Affiliated with
Tongji University. The committee director is Fu,Meng. The
Approval No. is 2015–045. The human adipose liposuction
liquid was obtained from the cosmetic plastic surgery hos-
pital with a consent statement by the patients.
hADSC isolation, expansion and characterization
hADSCs were isolated from human fresh adipose liposuc-
tion liquid according to previously published methods
[13,16]. Flow activated cell sorting (FACS, Beckman
Coulter) was carried out to identify the CD surface anti-
gen of the isolated hADSCs at passage 3 to 5 according to
published protocols [17,32]. Briefly, hADSCs cultured at
passage 3 to 5 were first collected by trypsin (0.25%) diges-
tion, washed with flow wash buffer (1 × Dulbecco’s
phosphate-buffered saline, 0.5% BSA, and 0.1% sodium
azide), and blocked with wash buffer supplemented with
mouse immunoglobulin G (25 μg/ml) for 10 minutes on
ice. A total of 100 μl of this cell suspension (approximately
5 × 105cells) was aliquoted per tube. Antibodies conju-
gated with either tricolor fluorescein isothiocyanate
(FITC), phycoerythrin (PE), or allophycocyanin (APC)
were purchased including CD44-APC (Cat#47-0441-80,
eBioscience), CD29-FITC (Cat#11-0299-41, eBioscience),
CD105-PE (Cat#12-1057-41, eBioscience), CD73-FITC
(Cat#11-0739-42, eBioscience), CD34-FITC (Cat#11-
0349-41, eBioscience), CD45-FITC (Cat#11-9459-41,
eBioscience). Matched isotype control combinations were
performed to identify the specific interaction of antigen
and antibody.
Middle cerebral artery occlusion mouse model
MCAO mouse was achieved through surgery on C57/
BL6 mice as previously described [17,24]. Briefly, six- to
eight-week old C57/BL6 mice were housed in a con-
trolled SPF level environment (12 hour light/dark cycle
at 21C) with free access to water and standard chow
diet. Anesthesia was induced by intraperitoneal injection
of chloral hydrate (2%, w/v) at 0.15 ml/10 g body weight.
A small incision was made above the rhinal fissure to
expose and isolate the right common cerebral artery
(CCA) and the branch of the cerebral artery. The CCA
branch was permanently ligated just before its bifur-
cation into the frontal and parietal branches with a 9–0
suture. The external common carotid artery was then
permanently ligated at two sites and cut off at the mid-
dle of the two sites. The internal common carotid artery
was temporarily ligated. A breach was made between the
bifurcation and the ligation site on the middle cerebral
artery to let the embolus (Cat#2634-A4, Beijing Sunbio
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common carotid artery reach to a depth of about 18 mm.
This occlusion was kept for 1.5 hours. Re-perfusion was
achieved by carefully taking out the embolus to avoid
bleeding. Then, the stitching and necessary sterilization
were done. Mice receiving surgery were evaluated for their
neurological function following the Rogers Scale score sys-
tem [24,33]. The successful MCAO mice with a score be-
tween 2 and 3 were randomly grouped as the PBS control
group (MCAO-Ctrl-PBS) and the hADSC injection group
(MCAO-hADSC). To confirm the safety of the surgery, a
sham group (MCAO-Sham) which underwent blood ves-
sel exposure without occlusion was also included as the
normal control.hADSC labeling and stereotactic injection into MCAO
brain injury area
To trace exogenously introduced hADSCs in the MCAO
brain, enhanced GFP (EGFP) expressing lentivirus FG12
was packaged and infected into hADSCs before injec-
tion. hADSCs were observed 48 hours after infection
under a fluorescent microscope at a wavelength of 488
nm. A total of 80% to 90% percent of hADSCs labeled
with green fluorescence was regarded as successful in-
fection. Then, EGFP-hADSCs were collected and ad-
justed to a final concentration of 1 × 109 cells/ml
suspended in PBS. An amount of 5 μl of this cell suspen-
sion was injected into the MCAO mouse brain injury
area through a glass micropipette and stereotaxic in-
jector (KDS310, Muromachi-Kikai). Briefly, we injected
5 μl cell suspension from three directions within one
pole at the infarct lesion. This injection process took six
minutes. After injection, the syringe was kept in the
brain tissue for one minute to achieve good absorption.
In parallel, 5 μl of PBS was injected into the control
MCAO group of mice. For the sham group, nothing was
done.Neurological function evaluation by the Rogers Scaling
System
Each mouse was neurologically evaluated with the Rog-
ers Scaling System by two researchers who were blinded
to the experimental groups. The scale categories used
followed those previously reported [24,33]. The Rogers
Scale score functional status was defined as follows: no
deficit (0); failure to extend left forepaw (1); decreased
grip of the left forelimb when the tail is pulled (2); spon-
taneous movement in all directions, contralateral circling
if pulled (3); circling or walking to the left (4); move-
ment only when stimulated (5); unresponsive to stimula-
tion (6); and dead (7). Scoring was done every week and
the statistical analysis was carried out with GraphPad
Prism 5.Mouse brain infarction area determined with TTC staining
TTC staining was performed as previously described
[34]. After the mice were sacrificed, the cerebrum was
immediately removed and put in a −4°C refrigerator for
20 minutes. Then it was sliced into six uniform coronal
sections after the olfactory bulb was removed. The sec-
tions were placed in 2% (W/V in PBS) 2,3,5-triphenyltet-
razolium chloride (TTC, Cat# T8877, Sigma) at 37°C in
a water bath, then fixed with 4% paraformaldehyde. The
normal brain tissue was dyed pink while the infarction
area was pale. The infarction area of every six sections
was measured by using image analysis software (Scion
Image) and the volume of cerebral infarction was esti-
mated by cerebral infarction = the infarction area ×
thickness/2.Mouse spatial learning and memory evaluation by the
Morris test
To evaluate the hADSC rescuing function for mouse
spatial learning and memory, a Morris water maze
equipped with a digital camera was used to determine
these important physiological indexes for post-stroke
mice. The protocols follow those published by Diederich
et al. and Vorhees et al. [35,36]. To perform a Morris
test, a program was set as follows: five day training by
putting each mouse in sequence into the water from
each of the four directions every day. During this
process, the same mouse should be put into the water
with an interval of at least 20 mintutes. Also, when the
mouse finishes swimming, keeping it warm was a prior-
ity. The longest tracing time lasts for 120 seconds. The
fifth day repeats the first day program. The sixth day is
the test day with the mice starting from the opposite
side of the escape platform. The data were recorded and
handled with Any-maze software (EthoVision XT7.0,
Noldus Information Technology b.v., Netherlands).Immunohistochemistry staining to trace hADSC fate
The EGFP-hADSCs were traced by immunohistochemi-
cal staining with the neuronal markers MAP2
(Cat#188011, Synaptic Systems), GFAP (Cat#173011,
Synaptic Systems) and human nuclear antigen (HNA,
Cat#MAB1281) following previously published tech-
niques [13]. Briefly, after the Morris water maze test,
mice from each group were sacrificed and underwent in-
tracardial perfusion. Then the brain was removed, fixed
with paraformaldehyde and dehydrated with graded su-
crose. Brain sections were obtained at 20 μm with a
freezing section machine (Leica CM1850) and subjected
to histoimmunochemical staining. Whole brain scanning
was used to observe the distribution of the EGFP labled
hADSCs using a confocal microscope (Leica, SP8). Also,
co-localization was carefully observed to determine
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into neuronal cells.
qRT-PCR to detect the subtypes of brain cells
To further explore how the introduced hADSCs rescue
the mouse brain function, qRT-PCR was used to detect
the gene markers Iba1 and GFAP (for microglia cells),
NeuN and Synapsin (for neuron cells), and MBP (for oli-
godendrocytes). Their primer information is listed in
Table 1. The protocols were previously published [13].
Statistical analyses
All data are expressed as mean ± standard deviation (SD)
or standard error of the mean (SEM). The statistical sig-
nificance was determined using one-way or two-way ana-
lysis of variance (ANOVA) Bonferroni post-tests between
groups by GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego CA, USA). P<0.05 was
considered statistically significant.
Results
hADSC morphology and CD surface antigen profiling
Isolated hADSCs possess typical spindle-like morph-
ology after passage 3 to 5 as shown in Figure 1A. The
experimental design diagram is shown in Figure 1A. The
CD surface antigen expression pattern analyzed by flow
Jo software after FACS is shown in Figure 1B. More than
84.9% of the hADSCs express MSC CD markers, CD29,
CD44, CD73 and CD105, while no more than 0.86% of
the hADSCs express the hematopoietic stem cell
markers, CD34 and CD45.
Generation and characterization of MCAO mouse model
(stroke model)
The MCAO mouse model was made following a surgical
operation as shown in Figure 2A. The mice manifested
weakness in the contralateral limbs after the MCAOTable 1 Primer sequence for the related genes












Rev 5′-GCCTGCTCACCACCTTCTTGA-3′model was established. The representative images dem-
onstrating the abnormal behaviors are shown in
Figure 2B. To determine the area of the brain damaged
by infarction seven days after MCAO, TTC staining was
performed and the circled pale color as shown in
Figure 2C indicates the infarcted area. TTC staining re-
vealed significant damage to the brain, consistent with
the abnormal behavior. These data collectively con-
firmed the success of the MCAO mouse model. Accord-
ing to the Rogers Scale scoring, those mice receiving
MCAO surgery scaled as 2 to 3 scores were randomly
assigned to two groups: one used as the control group
with PBS injection only named MCAO-Ctrl-PBS (n = 7),
the other used as the cell injection group named
MCAO-hADSC (n = 7).
Functional improvements achieved by hADSC
transplantation in MCAO mice
Seven days after the MCAO surgery, EGFP-hADSCs or
PBS solution was stereostatically injected into the infarc-
tion area of the MCAO mouse brain. Their behaviors
were observed carefully and the score was recorded
every week according to the protocol diagram shown in
Figure 1A. The Rogers Scale scoring results are shown
in Figure 3A. Significant differences (P<0.05) could be
found between the MCAO-Ctrl-PBS group and the
MCAO-hADSC group at 7 days, 35 days, 42 days and 49
days after treatment. To better demonstrate the individ-
ual differences within each group, the dotting distribu-
tion is also shown in Figure 3A for reference. Seven
weeks after hADSCs injection, each group of mice was
subjected to the Morris Test. The experimental diagram
of the Morris Water Maze is shown in Figure 3B, the
water maze test duration (S) is shown in Figure 3C and
the tracking path information of representative mice in
each group is shown in Figure 3D (the tracking paths of







Figure 1 Experimental diagram (A), hADSC surface antigen profiling with FACS showed that hADSCs positively express CD29, CD44, CD73 and
CD105, negatively express CD34 and CD45 (B). FACS, flow activated cell sorting; hADSCs, human adipose-derived stem cells.
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the final test. The MCAO-hADSC group mice regained
the ability to memorize the target and took a nearly
equal time (P>0.05) to find the escape platform in as ef-
ficient a way as the MCAO-Sham group mice (P>0.05)
(Figure 3C, D, G), indicating a significant rescuing effect.
The MCAO-hADSC group mice took a significantly(P<0.001) shorter time to search around and find the
target compared with the MCAO-Ctrl-PBS group mice
(Figure 3C). Comparing the path length among each
group, mice in the MCAO-hADSC group went through
a shorter path length and took less time to reach the
rescuing platform than those in the MCAO-Ctrl-PBS
group at a similar swimming speed (Figure 3E-G). These
Figure 2 MCAO mouse model processing diagram (A), MCAO mouse model confirmation by abnormal behaviors (B), brain injury appearance
and TTC staining was used to confirm the success of the MCAO mouse model (C). MCAO, middle cerebral artery occlusion.
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latent time. Carefully observing the latent process, mice in
the MCAO-hADSC group were always more efficient in
reaching the rescue platform than those in MCAO-Ctrl-
PBS group, but were similar to those in the MCAO-Sham
group; the data are shown in Figure 3D and Additional
file 1: Video 1, Additional file 2: Video 2, Additional file 3:
Video 3, Additional file 4: Video 4, Additional file 5:
Video 5, Additional file 6: Video 6, Additional file 7:
Video 7, Additional file 8: Video 8 and Additional file 9:
Video 9. These data demonstrate that hADSCs trans-
plantation apparently improved the spatial learning and
memory of the MCAO mouse indicating their promis-
ing therapeutic effects on post-stroke patients.
Infarction volume was reduced by hADSC administration
TTC staining was used to determine the brain infarction
area. The representative pictures are shown in Figure 4A.
The infarction volume obtained statistically with Scion
Image is shown in Figure 4B. The infarction volume was
significantly (P<0.05) reduced in the MCAO-hADSC
group compared with the MCAO-Ctrl-PBS group, whichindicates the apparent treatment effects, at least in the
physical and appearance levels. This result was consist-
ent with those previously reported [17,23,24].
Transplanted hADSCs transdifferentiated into neuron-like
cells in vivo
Histoimmnochemical staining was used to trace the mi-
gration, transdifferentiation and integration of the intro-
duced hADSCs in vivo. The staining pictures and the
statistical analysis with neuronal markers MAP2 and
GFAP are shown in Figures 5 and 6 and Additional file
10: Figure S1 and Additional file 11: Figure S2 respect-
ively. Neuron-like cells could be found as shown in Add-
itional file 10: Figure S1. Statistical analysis found that a
similar (P>0.05) percentage of GFP positive cells existed
in both the contralateral brain area and the ipsilateral
brain area, which indicated their robust in vivo migra-
tion and survival ability (Figure 5C and D). Moreover,
co-localization of GFP and MAP2 was found at a rela-
tively higher (P<0.01) percentage in the contralateral
brain area indicating the neuron differentiation of intro-
duced hADSCs in a preferred in vivo environment
Figure 3 Rogers Scale scoring for three groups of mice and the score distribution within each group (A), water maze performing protocol
diagram and the test duration (S) for each group of mice (B and C), the water maze track path information for the representative mice within
each group (D), their total distance travelled (m), their average speed (m/s) and their path efficiency (%) on the test day (D6) (E to G). *,** and
*** indicate that significant differences were found between the groups (P <0.05, P <0.01 and P <0.001, respectively).
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in vivo transdifferentiation (Figure 5D). Meanwhile, a signifi-
cantly higher (P<0.001) percentage of MAP2 positive cells
was found between the MCAO-hADSC and MCAO-Ctrl-
PBS, also between the MCAO-Sham and MCAO-Ctrl-PBS
in both of the two brain spheres, but this significant differ-
ence was not found between MCAO-hADSC and MCAO-
Sham in both of the two brain spheres. On the other hand,
co-localization of GFP and GFAP was rarely found, implying
a minor transdifferentiation preference of hADSCs to GFAP
+ cells (Figure 6C and D), which agreed with previously pub-
lished results [13]. At the same time, it was observed that
the introduced hADSCs could significantly (P<0.001) sup-
press the reaction of GFAP expressing cells in both brainspheres compared with their counterparts in the PBS injec-
tion control group, implying their anti-inflammation effects
(Figure 6D). Colocalization of HNA and GFP could be ob-
served indicating that the GFP positive cells were indeed the
introduced hADSCs (Additional file 11: Figure S2).
hADSCs protect the endogenous neurons and
oligodendrocytes while suppressing microglia cells
qRT-PCR data indicated that hADSC administration can
significantly suppress the expression of the microglia
marker Iba1 (P<0.01) and the astrocyte marker GFAP
(P<0.05) (Figure 7A and D) compared with the PBS control
group. This demonstrated that hADSCs can decrease brain
inflammation by suppressing the reaction of microglia cells
Figure 4 Brain infarction volume determined by TTC staining. Representative TTC staining pictures of mouse brain within each group (A), and the statistical
analysis by Scion Image Software (B). * means significant differences were found between groups (P <0.05). TTC, 2,3,5-triphenyltetrazolium chloride.
Figure 5 hADSC tracing by histoimmunostaining with MAP2 antibody. MCAO mouse group with PBS injection instead of hADSC serving as the negative
control (MCAO-Ctrl-PBS) (A), normal mice with blood vessel exposure only but not occlusion (MCAO-Sham) (B), MCAO mouse group with hADSC injection
seven days after MCAO surgery (MCAO-hADSC) (C). Quantitative analysis of GFP labeled hADSCs, MAP2+ relative to the DAPI+ means neurons relative to
the total cells in both the ipsilateral and contralateral areas of different groups of the MCAO brain, GFP relative to the DAPI+ means the survival hADSCs take
the ratio of total brain cells, GFP+/MAP2+ relative to DAPI+ means the injected hADSCs which differentiated into MAP2+ cells take the ratio of total brain
cells (D). *, ** and *** indicates that significant differences were found between groups (P<0.05, P<0.01 and P<0.001, respectively ). DAPI, 4',6-diamidino-2-
phenylindole; hADSC, human adipose-derived stem cells; MAP2, microtubule-associated protein 2; MCAO, middle cerebral artery occlusion.
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Figure 6 hADSC tracing by histoimmunostaining with GFAP antibody. MCAO mouse group with PBS injection instead of hADSC serving as the negative
control (MCAO-Ctrl-PBS) (A), normal mice with blood vessel exposure only but not occlusion (MCAO-Sham) (B), MCAO mouse group with hADSC injection
seven days after MCAO surgery (MCAO-hADSC) (C). Quantitative analysis of GFP labeled hADSCs, GFAP+ relative to the DAPI+ means astrocytes cells take the
ratio of total cells in both the Ipsilateral and Contralateral of different groups of the MCAO brain, GFP relative to the DAPI+ means the survival hADSCs take
the ratio of total brain cells, GFP + /GFAP + relative to DAPI + means the hADSCs transdifferentiated into astrocytes take the ratio of total brain cells (D). *, **
and *** indicates that significant differences were found between groups (P<0.05, P<0.01 and P<0.001, respectively). DAPI, 4',6-diamidino-2-phenylindole;
GFAP, glial fibrillary acidic protein; hADSC, human adipose-derived stem cells; MCAO, middle cerebral artery occlusion.
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cantly (P<0.05) improve the neuron related genes NeuN
and Synapsin (Figure 7B and E) compared to the PBS
injected control group mice. This implies that introduced
hADSCs can protect the endogenous neuron from damage.
Also, the oligodendrocyte marker MBP was significantly
(P<0.05) improved compared with the PBS control group.
These accumulated data support the hypothesis that
hADSCs administration can apparently improve the endo-
environment and protect the neurons and oligodendro-
cytes from damage-derived cell death.
Discussion
hADSCs have been regarded as one of the most promising
stem cell candidates to be translated into clinical therapies
for many hard-to-treat diseases. Stroke patients have faced
medical and economic burdens due to limited available
treatments. Stem cell based replacement therapy became at-
tractive because of its potential to thoroughly resolve these
problems. hADSCs possess multipotency properties and canbe differentiated into neuron cells as demonstrated by many
authors [7,13,21]. Characterization of isolated cells indicated
that these isolated and expanded spindle like cells at passage
3 to 5 were mostly (>84.9%) composed of adipose derived
mesenchymal stem cells. This type of CD antigen profiling
is similar to the requirement for MSCs and adipose-derived
mesenchymal stem cells [37]. Based on our previous find-
ings with regard to hADSC treatment of traumatic brain in-
jury (TBI) in mice, hADSCs could survive in mouse brain
and reduce the injury lesion [13]. This study demonstrated
that the infarction area was reduced in MCAO mouse brain
and mouse memory and spatial learning were significantly
improved, which is consistent with the previously published
results [17,23,24]. Our results indicated that hADSC injec-
tion may promote endogenous neuron survival after stroke
damage, which is also consistent with previously published
results [21,25-27,38]. hADSC transplantation can signifi-
cantly suppress the reaction of GFAP and Iba1 expressing
cells indicating their immunomodulation. These results are
consistent with previously published findings [22,23,39].
Figure 7 qRT-PCR to detect different endogenous cell marker expression: (A) Iba1 for microglia cells, (B) NeuN for neurons, (C) MBP for oligodendrocytes,
(D) GFAP for astrocytes, (E) Synapsin for neurons. *, ** and *** indicate that significant differences were found between groups (P<0.05, P<0.01 and
P<0.001, respectively). GFAP, glial fibrillary acidic protein.
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hADSCs differ with each other due to different animal
models, various cell delivery methods and the time window
of cell introduction [17,24]. In our study, we injected
hADSCs into the mouse brain lesion using an in situ
method seven days after MCAO surgery. We could trace
the injected GFP labled hADSCs and observed GFP and
MAP2 double positive cells. This agrees with previously
published data [13,21,23]. With qRT-PCR, we further dem-
onstrated that hADSC injection could promote the survival
of endogenous neuron and oligodendrocyte cells and modu-
late the brain immune response. These results agree with
[14,17]. Although scientists have made diligent efforts to de-
termine how ADSCs rescue the brain function of ischemic
mice, many doubts still exist including whether hADSC de-
rived neurons can integrate into the neuronal circuitry, how
the hADSCs modulate the immune response to brain dam-
age, and so on. Further exploration should be performed to
make full use of ADSCs as the seeding cells for various
neurological diseases.
Conclusions
Presently, MSCs therapy is becoming a promising new
therapeutic option for stroke. Of all MSCs, ADSCs are of
special interest. Our results demonstrate that hADSC treat-
ment significantly promotes the spatial learning and mem-
ory of MCAO mice. Meanwhile, the infarction volume of
MCAO mice could also apparently be reduced implying
promising clinical treatment effects. Interestingly, in situ in-
troduced hADSCs were partially transdifferentiated into
MAP2 positive neuron-like cells with minor GFAP positive
ones in the in vivo microenvironment. This result implies
that probable stem cell replacement based therapy has oc-
curred. Meanwhile, injection of hADSCs could significantly
promote the survival of damaged neurons and oligodendro-
cyte cells. Moreover, significantly decreased expression of
GFAP and Iba1 in the MCAO-hADSC mouse group com-
pared with the MCAO-Ctrl-PBS mouse group showed that
an immunomodulatory function should occur due to
hADSC injection at the subacute phase of stroke disease.
Ongoing clinical trials should provide more useful and at-
tractive new information on the safety and efficacy of
hADSC for stroke patients in the very near future.
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